Key Dates

Related Announcements

• October 21, 2022 - Avenir Award Program for Genetic or Epigenetic of Substance Use Disorders (DP1 Clinical Trial Optional). See Notice PAR-23-021. 

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants regarding addition to the Section I and correction to the dates regarding Letters of Reference in the Section IV in PAR-23-021 “Avenir Award Program for Genetic or Epigenetics of Substance Use Disorders (DP1 - Clinical Trial Optional) ”.

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

The following text (in Bold Italic) has been added to the Section I.

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigations into the regulation of CNS gene expression is appropriate for this FOA as are investigations into the effects of gene expression or (epi)genetic variants on CNS cellular functions. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

A hyperlink to Frequently Asked Questions (FAQs) Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) is provided to assist Early Stage Investigators (ESI) in applying for this funding opportunity announcement. The URL for the FAQ web page is https://www.drugabuse.gov/about-nida/organization/divisions/division-neuroscience-behavior-dnb/related-funding-opportunities.

This announcement is focused on substance use disorders not their medical consequences. Applicants interested in medical consequences of substance use disorders should contact the program official(s) listed at end of this announcement about alternative funding opportunities.

Applications Not Responsive to this NOFO

The following types of studies are not responsive to this NOFO and will not be reviewed:

• Applications focused solely on the medical consequences of addiction.
• Applications focused solely on alcohol use disorder.

Section IV. Application and Submission Information

Currently, it reads

Letters of Reference:

Letters of reference are an important component of the application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference will be considered incomplete and will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their Commons accounts.

Letters may be submitted beginning September 19 and must be submitted no later than 5:00 p.m. (local time of applicant organization), October 19.

Revised to read (in Bold Italics):

Letters of Reference:

Letters of reference are an important component of the application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference will be considered incomplete and will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their Commons accounts.

Letters may be submitted beginning August 25 and must be submitted no later than 5:00 p.m. (local time of applicant organization), September 25 which also is the deadline for the application.

All other aspects of PAR-23-021 remain unchanged.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D
National Institute on Drug Abuse
Telephone: 301-435-1309
Email: [email protected]

John Satterlee, Ph.D.
National Institute on Drug Abuse
Telephone: 301-435-1020
Email: [email protected]